How is Rising Cancer Burden Driving Aspiration and Biopsy Needle Demand?

 The International Agency for Research on Cancer (IARC) states that “In 2018 there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide”. The organization also forecasts that by 2040, cancer will account for nearly 16.3 million deaths globally. Moreover, the World Health Organization (WHO) estimates that 2.26 million, 2.21 million, and 1.93 million new cases of breast cancer, lung cancer, and colon and rectum cancer were diagnosed in 2020. Additionally, the number of prostate, skin (non-melanoma), and stomach cancer cases is rising at an exponential rate.


The increasing cancer burden is encouraging healthcare companies and government organizations to work toward providing better diagnostic facilities, owing to which the aspiration and biopsy needles market will march at a CAGR of 7.2% during 2020–2030. The market was valued at $801.5 million in 2019, and it is expected to generate $1,717.9 million revenue by 2030. Biopsy and aspiration are performed to study the characteristics of tumors by analyzing a piece of the tissue or fluid under question.

Hospitals, diagnostic centers, research and academic institutes, and clinics use core needles and fine needles to study tumors. In the coming years, they will use a huge quantity of core needles, as biopsies through these needles help in easy differentiation between invasive and in situ breast tumors and identification of benign lesions. Currently, both these types of needles are being used to perform ultrasound-guided, stereotactic-guided, magnetic resonance imaging (MRI)-guided, and non-image-guided procedures on cancer patients.

Access Report Summary - Aspiration and Biopsy Needles Market  Business Strategies, and Regional Outlook

According to P&S Intelligence, North America was the largest user of aspiration and biopsy needles in the preceding years due to the soaring awareness regarding the early diagnosis of cancer, increasing number of U.S. Food and Drug Administration (USFDA) approvals for medical devices, and surging healthcare expenditure in the region. The American Cancer Society (ACS) estimates that over 1.9 million new cancer cases will be diagnosed in the U.S. and nearly 608,570 Americans will die of cancer in 2021.

Whereas, the Asia-Pacific (APAC) aspiration and biopsy needles market is projected to progress at the highest rate in the upcoming years. This will be due to the expanding pool of cancer patients and escalating public awareness regarding cancer diagnosis methods. For instance, according to the Australian Institute of Health and Welfare, 150,782 new cases of cancer will be diagnosed in Australia in 2021. Furthermore, the IARC estimates that 1,324,413 new cancer cases were recorded in India in 2020.

Therefore, the surging prevalence of cancer and increasing public awareness regarding its early diagnosis will fuel the usage of aspiration and biopsy needles in the foreseeable future.


Comments

Popular posts from this blog

Facial Skin Ablative Treatment Market To Reach $8,394.3 Million by 2030

Rising Spinal Cord Injury Volume to Drive Osseointegration Implants Market Growth